2015
DOI: 10.1038/srep18217
|View full text |Cite
|
Sign up to set email alerts
|

The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer

Abstract: Granulocyte-colony stimulating factor (G-CSF) producing malignant tumor has been reported to occur in various organs, and has been associated with poor clinical outcome. The aim of this study is to investigate the significance of tumor G-CSF expression in the chemosensitivity of uterine cervical cancer. The clinical data of recurrent or advanced cervical cancer patients who were treated with platinum-based chemotherapy were analyzed. Clinical samples, cervical cancer cell lines, and a mouse model of cervical c… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

11
139
0
1

Year Published

2016
2016
2020
2020

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 134 publications
(151 citation statements)
references
References 37 publications
11
139
0
1
Order By: Relevance
“…Tumor-related leukocytosis, which is occasionally encountered in patients with malignant tumors, is a paraneoplastic syndrome involving high leukocyte counts without underlying infection, bone marrow metastasis, or corticosteroid administration (1,2). Tumor-related leukocytosis is observed in 10% of patients with solid tumors and is associated with poor clinical outcome (3).…”
Section: Introductionmentioning
confidence: 99%
“…Tumor-related leukocytosis, which is occasionally encountered in patients with malignant tumors, is a paraneoplastic syndrome involving high leukocyte counts without underlying infection, bone marrow metastasis, or corticosteroid administration (1,2). Tumor-related leukocytosis is observed in 10% of patients with solid tumors and is associated with poor clinical outcome (3).…”
Section: Introductionmentioning
confidence: 99%
“…In 2012, there were an estimated 527,600 novel cervical cancer cases and 265,700 mortalities worldwide (1). Although the majority of patients can be cured with treatments based on surgery and radiotherapy, a significant number eventually develop recurrent disease, with the the risk of recurrence being 10-20% for patients with stage IB-IIA [International Federation of Gynecology and Obstetrics (FIGO) stage] and 50-70% for those in stages IIB-IVA2 (2,3). With advances in the development of molecular-targeted drugs, novel diagnostic and therapeutic molecular targets may enable the development of novel therapies for cervical cancer.…”
Section: Introductionmentioning
confidence: 99%
“…It was revealed that tumor-induced granulocyte colony-stimulating factor (G-CSF) is one of those factors (Waight et al 2011;Abrams and Waight 2012;Luyckx et al 2012;Kawano et al 2015). Our recent study also showed that the serum G-CSF level is associated with the inhibition of expansion and differentiation of G-MDSCs in tumor-bearing adiponectin knockout mice (Han et al 2013).…”
Section: The Subsets Of Mdscsmentioning
confidence: 91%